FY2018 EPS Estimates for Agile Therapeutics, Inc. (AGRX) Reduced by William Blair
Agile Therapeutics, Inc. (NASDAQ:AGRX) – Equities researchers at William Blair dropped their FY2018 EPS estimates for Agile Therapeutics in a note issued to investors on Wednesday. William Blair analyst T. Lugo now forecasts that the specialty pharmaceutical company will post earnings per share of ($0.59) for the year, down from their previous estimate of ($0.09). William Blair also issued estimates for Agile Therapeutics’ FY2019 earnings at $0.31 EPS.
Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings data on Friday, July 28th. The specialty pharmaceutical company reported ($0.26) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.02. During the same period in the prior year, the firm earned ($0.29) EPS. TRADEMARK VIOLATION NOTICE: This article was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.thecerbatgem.com/2017/10/15/fy2018-eps-estimates-for-agile-therapeutics-inc-agrx-reduced-by-william-blair.html.
A number of other equities research analysts also recently weighed in on AGRX. HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Agile Therapeutics in a report on Monday, October 2nd. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a report on Sunday, July 30th. ValuEngine downgraded Agile Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Janney Montgomery Scott reiterated a “buy” rating and issued a $13.00 target price (down from $15.00) on shares of Agile Therapeutics in a report on Thursday, August 24th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 target price on shares of Agile Therapeutics in a report on Thursday, September 21st. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $10.20.
Shares of Agile Therapeutics (NASDAQ AGRX) opened at 5.02 on Friday. Agile Therapeutics has a 52 week low of $1.82 and a 52 week high of $7.80. The company’s market capitalization is $144.61 million. The stock has a 50 day moving average price of $4.08 and a 200-day moving average price of $3.74.
In other news, Chairman Alfred Altomari acquired 10,000 shares of the firm’s stock in a transaction dated Friday, August 25th. The stock was purchased at an average price of $3.34 per share, for a total transaction of $33,400.00. Following the completion of the acquisition, the chairman now directly owns 161,587 shares in the company, valued at approximately $539,700.58. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 3.50% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AGRX. Royce & Associates LP increased its holdings in shares of Agile Therapeutics by 206.1% during the first quarter. Royce & Associates LP now owns 987,582 shares of the specialty pharmaceutical company’s stock valued at $3,165,000 after acquiring an additional 665,000 shares in the last quarter. Janney Montgomery Scott LLC bought a new stake in shares of Agile Therapeutics during the second quarter valued at approximately $122,000. LMR Partners LLP bought a new stake in shares of Agile Therapeutics during the second quarter valued at approximately $211,000. Franklin Resources Inc. increased its holdings in shares of Agile Therapeutics by 39.2% during the second quarter. Franklin Resources Inc. now owns 2,772,200 shares of the specialty pharmaceutical company’s stock valued at $10,396,000 after acquiring an additional 780,578 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Agile Therapeutics by 604.2% during the second quarter. Dimensional Fund Advisors LP now owns 95,820 shares of the specialty pharmaceutical company’s stock valued at $359,000 after acquiring an additional 82,213 shares in the last quarter. Hedge funds and other institutional investors own 67.59% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Stock Ratings for Agile Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics Inc. and related stocks with our FREE daily email newsletter.